Literature DB >> 22271757

Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis.

Valentina Carrai1, Irene Miniati, Serena Guiducci, Gloria Capaccioli, Renato Alterini, Riccardo Saccardi, Maria L Conforti, Luigi Rigacci, Giada Rotunno, Alberto Bosi, Marco Matucci Cerinic.   

Abstract

OBJECTIVE: Dysfunctional angiogenesis is a pathogenetic marker of SSc. Circulating levels of endothelial progenitor cells are reduced, and mesenchymal stromal cells show a reduced differentiation into endothelial cells and capacity to form capillaries. This suggests that pathophysiologically relevant changes may already exist in SSc bone marrow (BM) stromal cells that may affect downstream angiogenesis. The aim of this study is to evaluate, in SSc BM, angiogenesis, cellular immune system and fibrosis.
METHODS: Eight SSc patients affected by a severe dcSSc and screened for autologous haematopoietic stem cells transplantation (HSCT) underwent a BM biopsy. BM biopsies were compared with six healthy controls. To evaluate angiogenesis and cellular immunity, the following antibodies were used: vascular endothelial growth factor (VEGF), kinase insert domain-containing receptor/fetal liver kinase-1 (KDR/flk-1), MMP-9 and CD34. To evaluate fibrosis, silver impregnation for reticulum was used. The number of vessels, the mean area of vascularization, the perimeter and microvessel density (MVD) were measured with a multiparametric computerized imaging analysis.
RESULTS: A significant reduction in BM vascularity was found, while VEGF expression was much higher in SSc BM samples. Two patients had a Grade 2, whereas another two had a Grade 1 fibrosis.
CONCLUSION: In SSc, BM is characterized by a reduction of microvascular density and number of vessels and a significant increase of VEGF. This indicates that BM may be involved in the process of loss of angiogenesis, despite the presence of high local and systemic levels of VEGF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271757     DOI: 10.1093/rheumatology/ker447

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

Review 1.  Updates on morphea: role of vascular injury and advances in treatment.

Authors:  Julio C Sartori-Valinotti; Megha M Tollefson; Ann M Reed
Journal:  Autoimmune Dis       Date:  2013-11-12

2.  Collapsed Reticular Network and its Possible Mechanism during the Initiation and/or Progression of Hepatic Fibrosis.

Authors:  Shi-Lei Wen; Shi Feng; Shi-Hang Tang; Jin-Hang Gao; Lin-Hao Zhang; Huan Tong; Zhao-Ping Yan; Ding Zhi Fang
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

Review 3.  Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases.

Authors:  Liala Moschetti; Silvia Piantoni; Enrico Vizzardi; Edoardo Sciatti; Mauro Riccardi; Franco Franceschini; Ilaria Cavazzana
Journal:  Front Med (Lausanne)       Date:  2022-04-08

4.  Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis.

Authors:  Shadab Allipour Birgani; Marion Mailänder; Ines Wasle; Hermann Dietrich; Johann Gruber; Oliver Distler; Roswitha Sgonc
Journal:  Ann Rheum Dis       Date:  2015-09-11       Impact factor: 19.103

5.  Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis.

Authors:  Huayong Zhang; Jun Liang; Xiaojun Tang; Dandan Wang; Xuebing Feng; Fan Wang; Bingzhu Hua; Hong Wang; Lingyun Sun
Journal:  Arthritis Res Ther       Date:  2017-07-19       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.